Welcome to the Celgene REMS Program

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the Celgene products THALOMID® (thalidomide), REVLIMID® (lenalidomide) and POMALYST® (pomalidomide). The THALOMID REMS® program, REVLIMID REMS® program, and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene REMS programs, please click on the program name below:

- Revlimid REMS®
  Visit [www.REVLIIMIDREMS.com](http://www.REVLIIMIDREMS.com) to learn more about the REVLIIMID REMS® program.

- Pomalyst REMS®
  Visit [www.POMALYSTREMS.com](http://www.POMALYSTREMS.com) to learn more about the POMALYST REMS® program.

- THALOMID REMS®
  Visit [www.THALOMIDREMS.com](http://www.THALOMIDREMS.com) to learn more about the THALOMID REMS® program.

For prescribers, please enter your User Name and Password to manage your patients through a Celgene REMS program. If you do not have an online account, select Create User Account to establish an account. Patients currently enrolled in a Celgene REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

To login to your account:

- User Name
- Password

Forgot Password? • Login

Create User Account • Patient Surveys • Encuesta del paciente

Contact Us • Terms of Use • Privacy Policy
© 2005-2017, Celgene Corporation

Reference ID: 4439576
Home Page (after prescriber logon)

Click on a button below to access the corresponding REMS menu of operations for that product: enroll a patient, access an existing or save a new Patient-Physician Agreement Form, complete a prescriber survey or write a prescription.

For **REVLIMID REMS**

**RevlimidREMS**

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit [www.REVLIMIDREMS.com](http://www.REVLIMIDREMS.com) to learn more about the REVLIMID REMS® program.

For **POMALYST REMS**

**Pomalyst REMS**

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit [www.POMALYSTREMS.com](http://www.POMALYSTREMS.com) to learn more about the POMALYST REMS® program.

For **THALOMID REMS**

**ThalomidREMS**

Please see full Prescribing Information, including: Boxed WARNINGS, CONTRAINDICATIONS, PRECAUTIONS, and ADVERSE REACTIONS.

Visit [www.THALOMIDREMS.com](http://www.THALOMIDREMS.com) to learn more about the THALOMID REMS® program.

The Prescriber Dashboard is an optional resource that displays the status of patients under your care for a specific Celgene REMS program. A patient search function is also included to access detailed patient history information.

Select the “Manage My Account” button to view your Celgene REMS online account information.
REVLIMID REMS module

New PPAF/Patient Enrollment
Nueva inscripción de paciente

Work with Saved/Submitted PPAF Forms
Trabajar con formulario de acuerdo de paciente-médico guardado/entregado

Prescriber Survey
Encuesta de prescriptor

Standard Prescription Form

Veterans Health Administration Prescription Form
About the REVLIMID REMS® program

To avoid embryo-fetal exposure, REVLIMID is only available under a restricted distribution program called “REVLIMID Risk Evaluation and Mitigation Strategy (REMS).” Only certified prescribers can prescribe REVLIMID and only certified pharmacies can dispense REVLIMID in the REVLIMID REMS® program.

In order to receive REVLIMID, all patients must be enrolled in the REVLIMID REMS® program and agree to comply with the requirements of the REVLIMID REMS® program.

Key points of the REVLIMID REMS® program

Prescriber
- The prescriber enrolls and becomes certified with Celgene for the REVLIMID REMS®, program
- The prescriber counsels patient on benefits and risks of REVLIMID
- The prescriber provides contraception and emergency contraception counseling
- The prescriber verifies negative pregnancy test for all female patients of reproductive potential
- The prescriber completes a REVLIMID® (lenalidomide) Patient-Physician Agreement Form with each patient and sends it to Celgene
- The prescriber/patient completes applicable mandatory confidential survey
- The prescriber obtains an authorization number from Celgene and writes it on every prescription, along with the patient risk category
- The prescriber writes no more than a 4-week (28-day) supply, with no automatic refills or telephone prescriptions
- The prescriber sends REVLIMID prescription to certified pharmacy

Pharmacy
- The pharmacy certifies with Celgene for the REVLIMID REMS® program
- The certified pharmacy must obtain a confirmation number from Celgene before dispensing
- The certified pharmacy counsels the patient, and completes the Education and Counseling Checklist
- The certified pharmacy dispenses REVLIMID to patient along with a Medication Guide
Prescriber Resources

Enrolling in REVLIMID®
In order to prescribe REVLIMID®, you must enroll in the REVLIMID® REMS® program and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to the Celgene Customer Care Center at 1-888-432-0325.

Prescribing REVLIMID for your patients
In order to receive REVLIMID, your patients must also be enrolled in the REVLIMID REMS® program. You can enroll your patients and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there. Additionally, you can also enroll your patients by accessing the Celgene REMS mobile app for your iPad.

For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-800-423-5436.

Download the Celgene REMS mobile app to your iPad by clicking here:

For additional information about the REVLIMID REMS® program, please see the educational materials below.

Prescriber Guide to REVLIMID REMS® Program
REVLIMID REMS® At-A-Glance
Full Prescribing Information
Please report adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID to Celgene using any of the following methods.

### REPORTING TO CELGENE

<table>
<thead>
<tr>
<th>Online:</th>
<th><a href="http://www.celgene.com/contact-us/">www.celgene.com/contact-us/</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Email:</td>
<td><a href="mailto:drugsafety@celgene.com">drugsafety@celgene.com</a></td>
</tr>
<tr>
<td>Telephone:</td>
<td>1-908-673-9667</td>
</tr>
<tr>
<td>Toll-free:</td>
<td>1-800-640-7854 (Global Drug Safety &amp; Risk Management) or 1-888-423-5436 (Celgene Customer Care Center)</td>
</tr>
<tr>
<td>Fax:</td>
<td>1-908-673-9115</td>
</tr>
<tr>
<td>Mail to:</td>
<td>Global Drug Safety &amp; Risk Management Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901</td>
</tr>
<tr>
<td>Other:</td>
<td>Per individual agreement between the reporting organization and Celgene Global Drug Safety &amp; Risk Management</td>
</tr>
</tbody>
</table>

### REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID may also be reported to the FDA MedWatch Reporting System using any of the following methods.

<table>
<thead>
<tr>
<th>Online:</th>
<th><a href="https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm">https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Telephone:</td>
<td>1-800-FDA-1088</td>
</tr>
<tr>
<td>Fax:</td>
<td>1-800-FDA-0178</td>
</tr>
<tr>
<td>Mail to:</td>
<td>MedWatch 5800 Fishers Lane Rockville, MD 20852-9787</td>
</tr>
</tbody>
</table>

Privacy policy  |  Terms of Use  |  Site map  |  Contact us

REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
This website is intended for residents of the United States only.
REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of REVLIMID and any suspected pregnancy occurring during the treatment with REVLIMID may also be reported to the FDA MedWatch Reporting System using any of the following methods:

Online: https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm

Telephone: 1-800-FDA-1088

Fax: 1-800-FDA-0178

Mail to: MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ALBERT B DEISSEROTH
05/28/2019 10:54:44 AM